Abstract 1128: Comprehensive multi-omics analysis of colorectal cancer tumors in diverse populations
Brigette Waldrup(City of Hope), Enrique Velazquez‐Villarreal(City Of Hope National Medical Center), Carmen Chávez, Francisco J. Carranza-Chávez(City of Hope), Yonatan Amzaleg(City of Hope), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Yuxin Jin(Chongqing University), Charité Ricker(Keck Hospital of USC), Julie O. Culver(City of Hope), David W. Craig(City of Hope), Bodour Salhia(University of Southern California), John D. Carpten(City of Hope), Lourdes Baezconde-Garbanati(University of Southern California), Mariana C. Stern(University of Southern California), Mackenzie Postel(University of Southern California)
Cited by 1
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer
|JAMA Oncology|2016|722
The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth
|Journal of Clinical Investigation|2005|524